What the MHRA Pathways pause really tells us clinically
A detailed clinical analysis of the MHRA's letter pausing the Pathways trial, examining what it actually says and what important questions remain unanswered.21 February 2026
The pause on the Pathways trial has raised urgent questions for clinicians and patients alike. Rather than treating the MHRA letter as the final word, it is worth reading it carefully as a clinician would: examining what evidence it presents, what it acknowledges, and what it deliberately leaves unaddressed.
This analysis moves beyond the headlines to consider what a clinical reading of the letter reveals about the regulatory process, the trial design, and the gaps in our current understanding. There are legitimate questions to ask not just about why the trial was paused, but about whether we are focusing on the right outcomes and the right evidence.
Read the full piece to explore what the MHRA letter actually says, where the clinical concerns lie, and what questions we should be pressing for answers to.